Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

 Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

Myovant Sciences Reports Results of Relugolix Combination Therapy in P-III LIBERTY 1 Study for Uterine Fibroids in Women

Shots:

  • The P-III LIBERTY 1 study results involves assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg)/relugolix (40mg) as monothx. + relugolix combination therapy vs PBO in 388 women in ratio (1:1:1) with uterine fibroids and heavy menstrual bleeding for 24wks.
  • The P-III LIBERTY 1 study results: response rate (73.4% vs 18.9%); AEs (62% vs. 66%); 84.3% reduction in menstrual blood loss; maintained bone mineral density; reduction in pain; improvement in anemia; Improvement in QoL; well tolerated
  • Relugolix is an oral GnRH receptor antagonist, reduces the ovarian estradiol production and is also evaluated in P-III LIBERTY 2 study with its expected results in Q3’19 and NDA submission to the US FDA in Q4’19

Click here to read full press release/ article | Ref: Myovant | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post